Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene |
| |
Authors: | Francesco Saccà Angela Marsili Giorgia Puorro Antonella Antenora Chiara Pane Alessandra Tessa Pasquale Scoppettuolo Claudia Nesti Vincenzo Brescia Morra Giuseppe De Michele Filippo M Santorelli Alessandro Filla |
| |
Institution: | 1. Department of Neurological Sciences, University Federico II, Via Pansini 5, 80131, Naples, NA, Italy 2. Molecular Medicine, IRCCS Stella Maris, Pisa, Italy
|
| |
Abstract: | Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 % of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 % of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. l-Buthionine-sulphoximine treatment of the proband’s lymphoblasts showed a severe phenotype as compared to classic FRDA. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|